- Home
- TWST
as 04-01-2025 4:00pm EST
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well-plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies and powers cost-effective, rapid high-throughput synthesis, enabling researchers to realize opportunities ahead rapidly. Geographically, it derives a majority of its revenue from the United States.
| Founded: | 2013 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 2.6B | IPO Year: | 2018 |
| Target Price: | $52.50 | AVG Volume (30 days): | 998.0K |
| Analyst Decision: | Buy | Number of Analysts: | 10 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.38 | EPS Growth: | N/A |
| 52 Week Low/High: | $27.41 - $60.90 | Next Earning Date: | 05-01-2025 |
| Revenue: | $330,189,000 | Revenue Growth: | 25.85% |
| Revenue Growth (this year): | 22.62% | Revenue Growth (next year): | 17.76% |
Stock Insider Trading Activity of Twist Bioscience Corporation (TWST)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Leproust Emily M. | TWST | Chief Executive Officer | Mar 20 '25 | Sell | $41.68 | 1,726 | $71,932.78 | 660,966 | |
| Cho Dennis | TWST | See Remarks | Mar 20 '25 | Sell | $41.68 | 230 | $9,585.48 | 111,662 | |
| Cho Dennis | TWST | See Remarks | Mar 14 '25 | Sell | $40.05 | 92 | $3,684.42 | 111,662 | |
| Leproust Emily M. | TWST | Chief Executive Officer | Mar 6 '25 | Sell | $40.91 | 2,402 | $98,273.03 | 660,966 | |
| Green Paula | TWST | SVP of Human Resources | Mar 6 '25 | Sell | $40.91 | 918 | $37,558.13 | 130,912 | |
| Cho Dennis | TWST | See Remarks | Mar 6 '25 | Sell | $40.91 | 277 | $11,332.90 | 111,662 | |
| WERNER ROBERT F. | TWST | Chief Accounting Officer | Mar 6 '25 | Sell | $40.91 | 241 | $9,860.03 | 51,434 | |
| Leproust Emily M. | TWST | Chief Executive Officer | Feb 21 '25 | Sell | $44.18 | 2,790 | $123,253.83 | 660,966 | |
| Green Paula | TWST | SVP of Human Resources | Feb 21 '25 | Sell | $44.18 | 618 | $27,301.39 | 130,912 | |
| Cho Dennis | TWST | See Remarks | Feb 21 '25 | Sell | $44.18 | 526 | $23,237.10 | 111,662 |
Latest Twist Bioscience Corporation News
TWST Breaking Stock News: Dive into TWST Ticker-Specific Updates for Smart Investing
Zacks
2 days ago
The Zacks Analyst Blog Highlights Illumina, BEAM, Twist Bioscience, Wave Life Sciences and CRISPR Therapeutics
Business Wire
2 days ago
Twist Bioscience and Curio Genomics Collaborate to Accelerate and Streamline NGS Adoption in Agrigenomics
Insider Monkey
13 days ago
Twist Bioscience (TWST): The Worst High-Risk High-Reward Growth Stock to Buy
Zacks
21 days ago
Twist Bioscience (TWST) Moves 6.6% Higher: Will This Strength Last?
Business Wire
22 days ago
Twist Bioscience Offers Clonal Genes for Global Academic Researchers at Express Speed for No Extra Cost
Insider Monkey
a month ago
Is Twist Bioscience Corporation (TWST) The Best Immunology Stock To Buy Now?
Business Wire
a month ago
Twist Bioscience to Present at Upcoming Investor Conferences
Business Wire
a month ago
Twist Bioscience Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Compare TWST vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "TWST Twist Bioscience Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.